

## Special Issue

# Pathogenesis and Natural History of Myeloproliferative Neoplasms

### Message from the Guest Editor

Myeloproliferative Neoplasms (MPNs) are a heterogeneous group of clonal hemopoietic stem cell disorders with unique clinical-pathological and molecular features. Over the last decades, the field of MPNs has undergone dramatic changes, as a consequence of a better understanding of their biology and natural history. Driver genetic events (e.g. BCR-ABL1 fusion gene; JAK2, CALR and/or MPL mutations) and MPN-related molecular derangements have been widely characterized and have fostered the development of new target therapies. MPNs are thus a paradigmatic example of how the integration of basic sciences and applied research expands our knowledge of human diseases and improves their clinical management. Within this framework, this Special Issue will address the pathogenesis, molecular biology and natural history of Chronic Myeloid Leukemia, Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis and cutaneous/systemic Mastocytosis .

### Guest Editor

Dr. Marco Pizzi

Pathology Unit, Department of Medicine—DIMED, University of Padova  
School of Medicine, 35128 Padova, Italy

### Deadline for manuscript submissions

closed (30 September 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/66228](https://mdpi.com/si/66228)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)